- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01925092
Mifepristone in Children With Refractory Cushing's Disease
July 31, 2014 updated by: Corcept Therapeutics
An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease
Study objectives are to obtain safety, pharmacokinetic, and pharmacodynamic data on the effect of mifepristone on glucose metabolism, body weight and the growth-hormone-IGF in children with refractory Cushing's disease.
Study Overview
Detailed Description
The study is being done to examine the effects of a medication called mifepristone in children with Cushing's disease.
Since a child's body may absorb and use mifepristone in a different way than adults, it is important to have information about the amount of mifepristone to give children and what will happen to it.
Mifepristone has been FDA approved for use only in adults with Cushing's syndrome, and it is important to learn if mifepristone improves the symptoms and signs of Cushing's disease in children.
The study is limited to children with Cushing's syndrome due to a pituitary tumor (Cushing's disease) and will not enroll children with Cushing's syndrome due to other causes.
The study will investigate how children's bodies absorb and process mifepristone, how it works in children and what effect it has on the use of sugar in the body, on the child's weight and on growth hormone.
An important part of the study is to evaluate the side effects of mifepristone in children.
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892-1103
- National Institute of Child Health and Human Development (NICHD)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 17 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females 6-17 years at informed consent
- Active Cushing's disease as demonstrated by the following:
- 24 hour Urinary Free Cortisol greater than the upper limit of normal for age on two urine collections during screening and
- midnight serum cortisol >4.4 mcg/dL (mean of two determinations on a single day at 2330 and 2400 during screening)
- Previous trans-sphenoidal surgery (TSS) for ACTH secreting pituitary tumor at least 3 months prior to screening
- Increased body weight defined by BMI Z-score of 1.5 or above
- Able to provide consent/assent
- Able to swallow study drug tablets (not crushed or split)
- Willing to use non-hormonal method of contraception in patients of reproductive potential
- Primary health care provider in home location
Exclusion Criteria:
- Hypercortisolism not due to Cushing's disease.
- Type 1 diabetes mellitus
- HbA1c ≥9.5% at Screening
- Body weight <25 kg
- Use of certain medications that are CYP3A substrates with narrow therapeutic ranges, such as simvastatin, lovastatin, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus during the 4 weeks prior to starting study drug. Use of these medications is also prohibited until 2 weeks after end of dosing.
- Use of certain medications that are strong CYP3A inhibitors such as itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir, fosamprenavir, boceprevir, clarithromycin, conivaptan, lopinavir, mibefradil, posaconazole, saquinavir, telaprevir, telithromycin, and voriconazole during the 2 weeks prior to starting study drug. Use of these medications is also prohibited until 2 weeks after end of dosing. Grapefruit and grapefruit juice, as well as grapefruit-related fruits and their juice (e.g. Seville oranges, pomelos), are prohibited during this time frame.
- Use of certain medications that are strong inducers of CYP3A such as rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, St. John's wort during the 2 weeks prior to starting study drug. Use of these medications is also prohibited until 2 weeks after end of dosing.
- Use of medications used to treat hypercortisolism from the duration indicated below prior to Day 1. Use of the medications is also prohibited until after the end of study 4 week follow up visit.
- steroidogenesis inhibitors such as ketoconazole, metyrapone: 4 weeks
- cabergoline, bromocriptine, somatostatin analogs such as octreotide, lanreotide, pasireotide long acting formulations: 8 weeks (immediate release formulations: 2 weeks)
- mitotane: 8 weeks
- Use of systemic glucocorticoid medications beginning 1 month prior to screening or anticipated use of these medications except for the treatment of adrenal insufficiency. Use of glucocorticoid medications is prohibited during the study until after the end of study 4 week study visit.
- Inflammatory, rheumatological, proliferative or other disorder(s) that would be anticipated to worsen with glucocorticoid blockade (e.g. inflammatory bowel disease, rheumatoid arthritis, psoriasis, etc.).
- Uncontrolled hypo- or hyperthyroidism.
- Uncorrected hypokalemia (<3.5 mEq/L). The screening period may be used to correct hypokalemia prior to starting study drug. Use of potassium and/or mineralocorticoid antagonists is permitted during the study.
- QTc ≥450 msec on Screening electrocardiogram
- Unexplained vaginal bleeding in females and/or any history of endometrial pathology.
- Positive pregnancy test in females.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: mifepristone
Daily doses of mifepristone over 84 days.
|
tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: collected during the12 week study and 4 week follow-up period; up to 16 weeks total.
|
Patients who have received at least 1 dose of mifepristone will be included in the safety evaluations.
|
collected during the12 week study and 4 week follow-up period; up to 16 weeks total.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (ANTICIPATED)
December 1, 2016
Study Registration Dates
First Submitted
August 8, 2013
First Submitted That Met QC Criteria
August 16, 2013
First Posted (ESTIMATE)
August 19, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
August 4, 2014
Last Update Submitted That Met QC Criteria
July 31, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Hypothalamic Diseases
- Hyperpituitarism
- Pituitary Diseases
- Adenoma
- Pituitary Neoplasms
- ACTH-Secreting Pituitary Adenoma
- Pituitary ACTH Hypersecretion
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Abortifacient Agents
- Luteolytic Agents
- Abortifacient Agents, Steroidal
- Contraceptives, Postcoital, Synthetic
- Contraceptives, Postcoital
- Menstruation-Inducing Agents
- Mifepristone
Other Study ID Numbers
- 13-CH-0170
- 02811-12 (OTHER: NICHD)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cushing's Disease
-
Sheffield Teaching Hospitals NHS Foundation TrustHRA PharmaCompleted
-
RECORDATI GROUPRecruitingEndogenous Cushing's SyndromeUnited States, Germany, France
-
Corcept TherapeuticsCompleted
-
Cortendo ABCompletedEndogenous Cushing's SyndromeUnited States, Bulgaria, Denmark, France, Greece, Hungary, Israel, Italy, Netherlands, Poland, Romania, Spain
-
Wuerzburg University HospitalCompletedEndogenous Cushing's SyndromeGermany
-
Cortendo ABCompletedEndogenous Cushing's SyndromeUnited States, Serbia, Denmark, Italy, Spain, Poland, Belgium, Bulgaria, Canada, Czechia, France, Germany, Israel, Netherlands, Turkey
-
University of OxfordAstraZenecaCompletedIatrogenic Cushing's DiseaseUnited Kingdom
-
Andrea M. IsidoriCompletedCushing's Syndrome CardiomyopathyItaly
-
Memorial Sloan Kettering Cancer CenterRecruitingCushing Syndrome | Cushing's Disease | Cushing DiseaseUnited States
-
Sparrow PharmaceuticalsRecruitingCortisol; Hypersecretion | Cortisol Overproduction | Cushing's Syndrome I | Cushing Disease Due to Increased ACTH Secretion | Cortisol Excess | Ectopic ACTH SecretionUnited States, Bulgaria, Romania
Clinical Trials on mifepristone
-
Corcept TherapeuticsCompletedPsychotic Disorders | Major Depressive DisorderUnited States
-
BioPro Medical LtdCompletedUterine Fibroid | Vaginal Bleeding.Israel
-
Corcept TherapeuticsRecruitingDiabetes Mellitus, Type 2 | HypercortisolismUnited States
-
Hadassah Medical OrganizationCompleted
-
VGX Pharmaceuticals, LLCCompletedHIV InfectionsUnited States
-
Cairo UniversityUnknown
-
University of ManitobaManitoba HarvestCompletedDiabetes Prevention | Obesity PreventionCanada
-
Gynuity Health ProjectsCompletedInduced AbortionGeorgia, Vietnam
-
University Hospital Inselspital, BerneUnknownCesarean DeliverySwitzerland
-
Planned Parenthood League of MassachusettsRecruiting